2022
Manifestations of Sickle Cell Disorder at Abdominal and Pelvic Imaging.
Solomon N, Segaran N, Badawy M, Elsayes KM, Pellerito JS, Katz DS, Moshiri M, Revzin MV. Manifestations of Sickle Cell Disorder at Abdominal and Pelvic Imaging. RadioGraphics 2022, 42: 1103-1122. PMID: 35559660, DOI: 10.1148/rg.210154.Peer-Reviewed Educational MaterialsConceptsSickle cell disordersMultisystem organ damageCharacteristic clinical syndromeTreatment of patientsPelvic imaging studiesDiagnosis of patientsSickle-shaped red blood cellsEvaluation of manifestationsPelvic manifestationsFunctional aspleniaRed blood cellsClinical presentationOrgan damageOrgan ischemiaSCD complicationsClinical syndromeRecurrent episodesUncommon sequelaVascular occlusionImaging featuresHematologic disordersDisease manifestationsIllness leadCell disordersOnline supplemental materialRefractory autoimmune hemolytic anemia in a systemic lupus erythematosus patient: A clinical case report
Crawford LR, Neparidze N. Refractory autoimmune hemolytic anemia in a systemic lupus erythematosus patient: A clinical case report. Clinical Case Reports 2022, 10: e05583. PMID: 35340637, PMCID: PMC8933632, DOI: 10.1002/ccr3.5583.Peer-Reviewed Original ResearchAutoimmune hemolytic anemiaSystemic lupus erythematosusRefractory autoimmune hemolytic anemiaHemolytic anemiaMycophenolate mofetilWarm autoimmune hemolytic anemiaSystemic lupus erythematosus patientsIntravenous immune globulinLupus erythematosus patientsClinical case reportNovel therapeutic modalitiesB cell proliferationImmune globulinSystemic lupusLupus erythematosusPediatric casesAdult casesCase reportHematologic disordersPlasma cellsTherapeutic modalitiesPatientsBeneficial responseAnemiaIndividuals/year
2021
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, Coulter DW, Diamond E, Flagg A, Goodman AM, Goyal G, Gratzinger D, Hendrie PC, Higman M, Hogarty MD, Janku F, Karmali R, Morgan D, Raldow AC, Stefanovic A, Tantravahi SK, Walkovich K, Zhang L, Bergman MA, Darlow SD. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2021, 19: 1277-1303. PMID: 34781268, DOI: 10.6004/jnccn.2021.0053.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHistiocytic neoplasmsNCCN Clinical Practice GuidelinesCommon histiocytic disorderRare hematologic disorderRosai-Dorfman diseaseTreatment of adultsClinical practice guidelinesErdheim-Chester diseaseLangerhans cell histiocytosisNCCN guidelinesSelect patientsSystemic therapyLymph nodesClinical presentationMild diseaseCell histiocytosisHematologic disordersHistiocytic disorderPractice guidelinesOptimal managementPatientsNeoplasmsSoft tissueDiseaseDisorders
2020
Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy
Zeidan A, Boddu P, Wood B, Zelterman D, Little R, Ivy S, Caldwell A, Sanchez-Espiridion B, Alatrash G, Sharon E, Radich J. Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy. Blood 2020, 136: 11-12. DOI: 10.1182/blood-2020-139752.Peer-Reviewed Original ResearchEvent-free survivalDuration of responseMRD-negative CRIntensive chemotherapyOverall survivalDay 1Complete remissionFree survivalHematologic improvementOlder patientsSecondary AMLPD-1Study armsAML patientsInitial treatmentHematologic disordersLeukemia-specific T-cell responsesCancer Therapy Evaluation ProgramCR/complete remissionImmune cell subsets analysisRandomized phase 2 studyRandomized phase 2 trialRandomized phase II studyAllogeneic stem cell transplantBetter long-term clinical outcomesHematologic Disorders
Amin H, Schindler J. Hematologic Disorders. 2020, 193-201. DOI: 10.1007/978-3-030-52552-1_15.ChaptersHematological conditionsStrong family historyHypercoagulable panelStroke therapeuticsIschemic strokeSecondary preventionStroke neurologistsYounger patientsAcute treatmentHypercoagulable conditionsHematologic disordersFamily historyHematological disordersClot formationCoagulation cascadeStrokePatientsDisordersNeurologistsPrevention
2019
From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?
Bewersdorf JP, Ardasheva A, Podoltsev NA, Singh A, Biancon G, Halene S, Zeidan AM. From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities? Blood Reviews 2019, 37: 100587. PMID: 31400824, DOI: 10.1016/j.blre.2019.100587.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyeloid neoplasmsClonal hematopoiesisTherapy-related myeloid neoplasmsAnnual progression rateHealthy elderly individualsGenetic testing resultsCardiovascular mortalityHematologic disordersMyeloid leukemiaClinical significanceProgression ratePremalignant stateElderly individualsDiagnostic criteriaPreventive opportunitiesSolid tumorsClinical settingNatural historyFurther studiesPatientsSomatic mutationsRiskHematopoiesisCurrent understandingICUs
2018
The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum
Ashchyan HJ, Butler DC, Nelson CA, Noe MH, Tsiaras WG, Lockwood SJ, James WD, Micheletti RG, Rosenbach M, Mostaghimi A. The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum. JAMA Dermatology 2018, 154: 409-413. PMID: 29450453, PMCID: PMC5876860, DOI: 10.1001/jamadermatol.2017.5978.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseHematologic malignant neoplasmsMedical comorbiditiesMalignant neoplasmsAssociation of agePyoderma gangrenosumClinical presentationBowel diseaseHematologic disordersMulticenter retrospective cohort studyTertiary academic referral centerInflammatory neutrophilic dermatosisPatients 65 yearsRetrospective cohort studyAcademic referral centerAge-specific evaluationPennsylvania Health SystemMassachusetts General HospitalLarge population studiesDifferent age groupsNeutrophilic dermatosisCohort studyInflammatory arthritisPatient demographicsReferral centerMore is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes
Shallis RM, Zeidan AM. More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. BMC Hematology 2018, 18: 4. PMID: 29435332, PMCID: PMC5796398, DOI: 10.1186/s12878-018-0095-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHigh-risk myelodysplastic syndromeMyelodysplastic syndromeAcute myeloid leukemiaAdministration scheduleOverall survivalLower-risk myelodysplastic syndromesAlternative administration schedulesOutcomes of patientsAlternative dosing schedulesRisk of progressionMeaningful clinical responsesAgent azacitidineAZA-001Clinical responseConventional careDosing schedulesPeripheral cytopeniasProspective studyClinical trialsHematologic disordersMyeloid leukemiaMost trialsResponse ratePatientsSystematic review
2017
Janus Kinase Inhibitors
Kim A, Strober B. Janus Kinase Inhibitors. 2017, 187-198. DOI: 10.1007/978-3-319-66884-0_19.Peer-Reviewed Original ResearchAutoinflammatory disordersJanus kinase inhibitorNovel drug classJanus kinaseMedication classesAtopic dermatitisRheumatoid arthritisAlopecia areataHematologic disordersClinical dataDrug classesPolycythemia veraTherapeutic benefitJAK inhibitorsNew agentsJAK-STAT pathwayClinical useJakinibsKinase inhibitorsActivator of transcriptionDisordersPreliminary findingsSignal transducerInhibitorsHuman use
2016
Hematologic Disorders
Amin H, Schindler J. Hematologic Disorders. 2016, 147-154. DOI: 10.1007/978-3-319-39605-7_15.Peer-Reviewed Original ResearchHematological conditionsStrong family historyHypercoagulable panelStroke therapeuticsIschemic strokeSecondary preventionStroke neurologistsYounger patientsAcute treatmentHypercoagulable conditionsHematologic disordersFamily historyHematological disordersClot formationCoagulation cascadeStrokePatientsDisordersNeurologistsPrevention
2015
Maternal disorders affecting labor and delivery
Merriam A, Sciscione A. Maternal disorders affecting labor and delivery. 2015, 283-347. DOI: 10.1002/9781118327241.ch13.Peer-Reviewed Original ResearchMedical conditionsHigh-risk medical conditionsManagement of anticoagulationStructural heart lesionsProcess of laborChronic hypertensionHypertensive disordersMaternal disordersAdverse outcomesHeart lesionsNeurologic conditionsHeart diseaseHematologic disordersFetal conditionInfectious diseasesDisordersFetusesMothersDiseaseWomenManagement strategiesDeliveryAnticoagulationHypertensionDiabetes
2013
Applications of high-throughput DNA sequencing to benign hematology
Sankaran VG, Gallagher PG. Applications of high-throughput DNA sequencing to benign hematology. Blood 2013, 122: 3575-3582. PMID: 24021670, PMCID: PMC3837507, DOI: 10.1182/blood-2013-07-460337.Peer-Reviewed Original ResearchConceptsHigh-throughput DNA sequencingDNA sequencingHigh-throughput DNA sequencing technologiesBlood cell lineagesDNA sequencing technologiesWhite blood cell lineagesComplex traitsGene discoverySequencing technologiesCell lineagesSequencingBenign hematologic disordersBenign hematologyDisease-specific complicationsGenomic biomarkersStratification of riskMonitoring of therapyNovel technologySignificant promiseDisease diagnosisRed blood cellsDisease progressionHematologic disordersClinical careTherapeutic strategies
2011
Targeted Gene Modification of Hematopoietic Progenitor Cells in Mice Following Systemic Administration of a PNA-peptide Conjugate
Rogers FA, Lin SS, Hegan DC, Krause DS, Glazer PM. Targeted Gene Modification of Hematopoietic Progenitor Cells in Mice Following Systemic Administration of a PNA-peptide Conjugate. Molecular Therapy 2011, 20: 109-118. PMID: 21829173, PMCID: PMC3255600, DOI: 10.1038/mt.2011.163.Peer-Reviewed Original ResearchConceptsGene modificationGene therapyHematopoietic stem cell gene therapyStem cell gene therapyGenomic modificationsVivo gene therapyCell gene therapyTargeted gene modificationVivo gene modificationHematopoietic progenitor cellsPeptide nucleic acidSystemic administrationBone marrowGene-targeting strategiesProgenitor cellsPrimary recipient miceStem cell mobilizationEx vivo manipulationSickle cell anemiaLymphoid cell lineagesDonor miceRecipient miceHematologic disordersInvasive alternativeCell mobilization
2006
Clinical Experience With Denileukin Diftitox (ONTAK)
Foss F. Clinical Experience With Denileukin Diftitox (ONTAK). Seminars In Oncology 2006, 33: 11-16. PMID: 16516670, DOI: 10.1053/j.seminoncol.2005.12.017.Peer-Reviewed Original ResearchConceptsIL-2 receptorCutaneous T-cell lymphomaT-cell lymphomaDenileukin diftitoxIntermediate affinity IL-2 receptorsHuman IL-2 receptorChronic lymphocytic leukemiaActivated T lymphocytesDiphtheria toxinClinical profileHodgkin's lymphomaHematologic disordersT lymphocytesLymphocytic leukemiaB cellsClinical experienceB lymphocytesLymphomaCytocidal actionNumber of leukemiasDiftitoxHigh affinity formCellular protein synthesisReceptorsLymphocytes
2005
Comparison of survival times in a transplant study of hematologic disorders
Fu P, Laughlin MJ, Zhang H. Comparison of survival times in a transplant study of hematologic disorders. Contemporary Clinical Trials 2005, 27: 174-182. PMID: 16326144, DOI: 10.1016/j.cct.2005.10.003.Peer-Reviewed Original ResearchConceptsHuman leucocyte antigenHematologic disordersWilcoxon testUnrelated donor graftsBone marrow transplantationLog-rank testUmbilical cord bloodEvaluation of survivalNeutrophil recoveryDonor graftsOverall survivalMarrow transplantationGraft sourceCancer patientsPatient populationClinical trialsEffective therapyHematologic malignanciesLeucocyte antigenCord bloodLog rankSurvival timePatientsPatient samplesTransplantation studies
1998
HLA-mismatched family donor transplants: a novel strategy as curative therapy for patients with hematologic disorders.
McGuirk JP, Seropian S, Cooper D. HLA-mismatched family donor transplants: a novel strategy as curative therapy for patients with hematologic disorders. The Cancer Journal 1998, 4: 278-86. PMID: 9815289.Peer-Reviewed Original Research
1995
Hematologic disorders and nonimmune hydrops fetalis
Arcasoy M, Gallagher P. Hematologic disorders and nonimmune hydrops fetalis. Seminars In Perinatology 1995, 19: 502-515. PMID: 8822334, DOI: 10.1016/s0146-0005(05)80057-6.Peer-Reviewed Original ResearchConceptsNonimmune hydrops fetalisHematologic disordersHydrops fetalisTwin-twin transfusionFetal blood lossGlucose-6-phosphate dehydrogenase deficiencyFinal common denominatorBlood lossHeart failureFetomaternal hemorrhageNonimmune hydropsErythrocyte lossDehydrogenase deficiencyErythrocyte abnormalitiesErythrocyte productionDisordersHemorrhageAnemiaFetalisAnasarcaTransfusionAscitesEdemaHydropsFailure
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply